Arsenite


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D000230 Adenocarcinoma PMID:38563870
MESH:D000306 Adrenal Cortex Neoplasms PMID:20448261
MESH:D001018 Aortic Diseases PMID:34339004
MESH:D001745 Urinary Bladder Diseases PMID:18728046; PMID:20423714
MESH:D001749 Urinary Bladder Neoplasms PMID:19397947; PMID:20186695; PMID:20448261; PMID:23876855
MESH:D001930 Brain Injuries PMID:33535132; PMID:34929507
MESH:D001943 Breast Neoplasms PMID:31646340
MESH:D001991 Bronchitis PMID:23876855
MESH:D002295 Carcinoma, Transitional Cell PMID:31047981
MESH:D002471 Cell Transformation, Neoplastic PMID:12488483; PMID:21344382; PMID:22011395; PMID:22387281; PMID:22447124; PMID:22613180; PMID:23643801; PMID:24004609; PMID:24704393; PMID:25493652; PMID:26783756; PMID:27470698; PMID:28501331; PMID:28688901; PMID:31009485; PMID:31047981; PMID:31781319; PMID:32822399; PMID:35124418; PMID:38563870
MESH:D002869 Chromosome Aberrations PMID:28688901
MESH:D003643 Death PMID:26796881
MESH:D003920 Diabetes Mellitus PMID:25000461
MESH:D004646 Emphysema PMID:22572560
MESH:D005234 Fatty Liver PMID:18296743; PMID:31546213
MESH:D005355 Fibrosis PMID:18296743
MESH:D006965 Hyperplasia PMID:18728046; PMID:19397947; PMID:20423714; PMID:20448261
MESH:D006984 Hypertrophy PMID:32385600
MESH:D007153 Immunologic Deficiency Syndromes PMID:20725942
MESH:D007249 Inflammation PMID:15454118; PMID:16459422; PMID:23876855
MESH:D007333 Insulin Resistance PMID:28952001; PMID:35090851
MESH:D007410 Intestinal Diseases PMID:32385600
MESH:D008103 Liver Cirrhosis PMID:18296743; PMID:31513886
MESH:D008113 Liver Neoplasms PMID:33010264
MESH:D008175 Lung Neoplasms PMID:16809336; PMID:19397947; PMID:23876855
MESH:D008325 Mammary Neoplasms, Experimental PMID:31646340
MESH:D009336 Necrosis PMID:18079140; PMID:18728046; PMID:9548797
MESH:D009358 Congenital, Hereditary, and Neonatal Diseases and Abnormalities PMID:27579588
MESH:D009389 Neovascularization, Pathologic PMID:15738583
MESH:D011297 Prenatal Exposure Delayed Effects PMID:25543096; PMID:35090851
MESH:D011629 Puberty, Precocious PMID:25543096
MESH:D011658 Pulmonary Fibrosis PMID:38703806; PMID:39405678
MESH:D012878 Skin Neoplasms PMID:19397947; PMID:22011395; PMID:23876855
MESH:D014571 Urologic Neoplasms PMID:23618899
MESH:D014594 Uterine Neoplasms PMID:20448261
MESH:D015431 Weight Loss PMID:34339004; PMID:37442281
MESH:D017240 Mitochondrial Myopathies PMID:24960579
MESH:D018149 Glucose Intolerance PMID:35090851
MESH:D018908 Muscle Weakness PMID:33053406
MESH:D019446 Endotoxemia PMID:36791901
MESH:D042822 Genomic Instability PMID:27470698
MESH:D048629 Micronuclei, Chromosome-Defective PMID:9057100
MESH:D050197 Atherosclerosis PMID:30376133
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:20725942; PMID:22688006; PMID:31513886; PMID:31546213; PMID:32385600; PMID:37955338
MESH:D058226 Plaque, Atherosclerotic PMID:30376133
MESH:D064420 Drug-Related Side Effects and Adverse Reactions PMID:34653941
MESH:D064806 Dysbiosis PMID:36791901

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.